Omar Yaxmehen Bello Chavolla, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mexico | 33 | 2024 | 777 | 3.000 |
Why?
|
Insulin Resistance | 11 | 2024 | 3985 | 1.490 |
Why?
|
Nutrition Surveys | 6 | 2024 | 1741 | 1.400 |
Why?
|
Diabetes Mellitus, Type 2 | 18 | 2022 | 12240 | 1.170 |
Why?
|
Diabetes Mellitus | 4 | 2024 | 5891 | 0.860 |
Why?
|
Intra-Abdominal Fat | 4 | 2022 | 623 | 0.820 |
Why?
|
Hyperlipidemia, Familial Combined | 2 | 2021 | 14 | 0.780 |
Why?
|
Metabolism | 1 | 2021 | 193 | 0.670 |
Why?
|
Meningitis, Aseptic | 1 | 2018 | 59 | 0.600 |
Why?
|
Cause of Death | 4 | 2024 | 3708 | 0.580 |
Why?
|
Cardiovascular Diseases | 8 | 2024 | 15652 | 0.580 |
Why?
|
Antigens, Viral | 1 | 2021 | 995 | 0.560 |
Why?
|
Independent Living | 1 | 2020 | 585 | 0.520 |
Why?
|
Body Composition | 3 | 2022 | 2439 | 0.520 |
Why?
|
Uric Acid | 1 | 2022 | 809 | 0.500 |
Why?
|
Cholesterol | 2 | 2024 | 2898 | 0.500 |
Why?
|
Aging | 5 | 2022 | 8731 | 0.490 |
Why?
|
Frail Elderly | 1 | 2020 | 785 | 0.480 |
Why?
|
Dementia | 2 | 2020 | 2744 | 0.470 |
Why?
|
Cardiovascular System | 1 | 2021 | 841 | 0.440 |
Why?
|
Hypertriglyceridemia | 3 | 2022 | 290 | 0.430 |
Why?
|
Cholesterol, LDL | 2 | 2021 | 2393 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2021 | 3223 | 0.410 |
Why?
|
Metabolic Diseases | 1 | 2019 | 687 | 0.410 |
Why?
|
Urinary Incontinence | 1 | 2017 | 491 | 0.410 |
Why?
|
Adiposity | 3 | 2022 | 1890 | 0.400 |
Why?
|
Glucose Clamp Technique | 4 | 2022 | 262 | 0.400 |
Why?
|
Models, Statistical | 3 | 2022 | 5089 | 0.400 |
Why?
|
Pandemics | 7 | 2022 | 8703 | 0.390 |
Why?
|
Comorbidity | 6 | 2022 | 10563 | 0.390 |
Why?
|
Hypercholesterolemia | 1 | 2019 | 1149 | 0.380 |
Why?
|
Bacteremia | 1 | 2018 | 989 | 0.370 |
Why?
|
Apolipoproteins B | 4 | 2021 | 384 | 0.340 |
Why?
|
Hyperlipoproteinemia Type IV | 2 | 2021 | 5 | 0.340 |
Why?
|
Lipids | 2 | 2018 | 3315 | 0.340 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15880 | 0.320 |
Why?
|
Humans | 66 | 2024 | 765968 | 0.320 |
Why?
|
Staphylococcal Infections | 1 | 2018 | 1393 | 0.320 |
Why?
|
Health Status Disparities | 1 | 2021 | 1880 | 0.320 |
Why?
|
Body Mass Index | 8 | 2022 | 13039 | 0.310 |
Why?
|
Middle Aged | 33 | 2024 | 223009 | 0.300 |
Why?
|
Area Under Curve | 3 | 2021 | 1638 | 0.300 |
Why?
|
Adult | 31 | 2024 | 223044 | 0.300 |
Why?
|
Hypertension | 4 | 2022 | 8626 | 0.300 |
Why?
|
Smoking | 1 | 2024 | 9081 | 0.280 |
Why?
|
Risk Factors | 15 | 2024 | 74840 | 0.280 |
Why?
|
Cognition | 2 | 2024 | 7049 | 0.270 |
Why?
|
Aged | 22 | 2024 | 171117 | 0.270 |
Why?
|
Male | 36 | 2024 | 363698 | 0.260 |
Why?
|
Female | 37 | 2024 | 396112 | 0.260 |
Why?
|
ROC Curve | 3 | 2021 | 3620 | 0.230 |
Why?
|
Cross-Sectional Studies | 12 | 2024 | 26318 | 0.220 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1789 | 0.220 |
Why?
|
Glucose Tolerance Test | 4 | 2022 | 1180 | 0.220 |
Why?
|
Fasting | 5 | 2021 | 1606 | 0.210 |
Why?
|
RNA, Viral | 2 | 2021 | 2864 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Alzheimer Disease | 2 | 2021 | 8730 | 0.200 |
Why?
|
Adipose Tissue | 3 | 2022 | 3312 | 0.190 |
Why?
|
Pancreas Transplantation | 1 | 2022 | 194 | 0.190 |
Why?
|
Obesity | 3 | 2022 | 13076 | 0.190 |
Why?
|
Blood Glucose | 7 | 2022 | 6424 | 0.190 |
Why?
|
Inflammation | 1 | 2021 | 10850 | 0.190 |
Why?
|
Syndrome | 2 | 2018 | 3271 | 0.190 |
Why?
|
Triglycerides | 5 | 2021 | 2441 | 0.190 |
Why?
|
Risk Assessment | 6 | 2024 | 24282 | 0.180 |
Why?
|
Apolipoprotein A-II | 1 | 2021 | 41 | 0.180 |
Why?
|
Cholesterol, VLDL | 1 | 2021 | 70 | 0.180 |
Why?
|
Neoplasms | 2 | 2021 | 22340 | 0.180 |
Why?
|
Guillain-Barre Syndrome | 1 | 2022 | 128 | 0.180 |
Why?
|
Physicians | 1 | 2019 | 4588 | 0.180 |
Why?
|
Obstetric Labor, Premature | 1 | 2022 | 268 | 0.180 |
Why?
|
Bullying | 1 | 2023 | 234 | 0.170 |
Why?
|
Asymptomatic Infections | 1 | 2021 | 136 | 0.170 |
Why?
|
Metabolomics | 2 | 2020 | 1668 | 0.170 |
Why?
|
Melanoma | 1 | 2018 | 5719 | 0.170 |
Why?
|
Hospitalization | 5 | 2023 | 10808 | 0.160 |
Why?
|
Osteoarthritis, Hip | 1 | 2024 | 408 | 0.160 |
Why?
|
Respiratory Rate | 1 | 2020 | 179 | 0.160 |
Why?
|
Cities | 1 | 2022 | 543 | 0.160 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2019 | 81 | 0.160 |
Why?
|
Geography | 1 | 2020 | 652 | 0.150 |
Why?
|
Comprehensive Health Care | 1 | 2019 | 123 | 0.150 |
Why?
|
Anthropometry | 1 | 2022 | 1338 | 0.150 |
Why?
|
Adaptive Immunity | 1 | 2023 | 734 | 0.150 |
Why?
|
Prediabetic State | 2 | 2021 | 548 | 0.150 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2022 | 746 | 0.140 |
Why?
|
Iran | 1 | 2020 | 761 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11868 | 0.140 |
Why?
|
Registries | 3 | 2022 | 8297 | 0.140 |
Why?
|
Prevalence | 3 | 2022 | 15842 | 0.140 |
Why?
|
Intensive Care Units | 2 | 2021 | 3800 | 0.140 |
Why?
|
Young Adult | 10 | 2022 | 59889 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2018 | 175 | 0.140 |
Why?
|
Adipokines | 1 | 2019 | 308 | 0.140 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59489 | 0.140 |
Why?
|
Mortality | 3 | 2022 | 2904 | 0.140 |
Why?
|
Incidence | 5 | 2022 | 21480 | 0.130 |
Why?
|
Quality of Life | 5 | 2024 | 13462 | 0.130 |
Why?
|
Sulfonylurea Compounds | 1 | 2018 | 221 | 0.130 |
Why?
|
Prospective Studies | 7 | 2024 | 54802 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12509 | 0.130 |
Why?
|
Retrospective Studies | 7 | 2023 | 81514 | 0.120 |
Why?
|
Age Factors | 3 | 2021 | 18380 | 0.120 |
Why?
|
Educational Status | 2 | 2023 | 2513 | 0.120 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 15398 | 0.120 |
Why?
|
Pancreas | 2 | 2022 | 1700 | 0.120 |
Why?
|
Fibroblast Growth Factors | 1 | 2021 | 871 | 0.120 |
Why?
|
Immunocompromised Host | 1 | 2020 | 866 | 0.120 |
Why?
|
Age of Onset | 1 | 2022 | 3344 | 0.120 |
Why?
|
Docosahexaenoic Acids | 1 | 2021 | 916 | 0.110 |
Why?
|
Triage | 1 | 2020 | 996 | 0.110 |
Why?
|
Vaccination | 2 | 2023 | 3426 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2022 | 1393 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 618 | 0.110 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1429 | 0.100 |
Why?
|
Nutritional Status | 1 | 2021 | 1620 | 0.100 |
Why?
|
Haplotypes | 1 | 2019 | 2728 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2354 | 0.100 |
Why?
|
Drug Resistance | 1 | 2018 | 1591 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2019 | 869 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1194 | 0.100 |
Why?
|
National Health Programs | 1 | 2015 | 443 | 0.100 |
Why?
|
Cohort Studies | 6 | 2021 | 41649 | 0.100 |
Why?
|
Diabetic Nephropathies | 1 | 2018 | 969 | 0.090 |
Why?
|
Activities of Daily Living | 1 | 2020 | 2415 | 0.090 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 7123 | 0.090 |
Why?
|
Dietary Fats | 1 | 2018 | 2002 | 0.090 |
Why?
|
Pituitary Neoplasms | 1 | 2019 | 1321 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2022 | 5343 | 0.090 |
Why?
|
Hospitals, Urban | 2 | 2022 | 493 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6499 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1829 | 0.080 |
Why?
|
Health Personnel | 2 | 2021 | 3390 | 0.080 |
Why?
|
Insulin | 5 | 2022 | 6599 | 0.080 |
Why?
|
Longitudinal Studies | 3 | 2022 | 14751 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14652 | 0.080 |
Why?
|
tau Proteins | 1 | 2019 | 2112 | 0.070 |
Why?
|
Adenoma | 1 | 2019 | 2152 | 0.070 |
Why?
|
United States | 4 | 2024 | 72903 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2023 | 12768 | 0.070 |
Why?
|
Veterans | 1 | 2021 | 2664 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2019 | 22223 | 0.070 |
Why?
|
Proteomics | 1 | 2020 | 3910 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10603 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2021 | 12976 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2310 | 0.060 |
Why?
|
Prognosis | 3 | 2022 | 29922 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3247 | 0.060 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2172 | 0.060 |
Why?
|
Databases, Factual | 1 | 2020 | 8067 | 0.060 |
Why?
|
Cluster Analysis | 2 | 2022 | 2721 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3251 | 0.050 |
Why?
|
Adolescent | 4 | 2021 | 88835 | 0.050 |
Why?
|
Blood Pressure | 1 | 2019 | 8532 | 0.050 |
Why?
|
Internship and Residency | 1 | 2023 | 5946 | 0.050 |
Why?
|
Phenotype | 1 | 2021 | 16721 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9443 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7838 | 0.050 |
Why?
|
Latin America | 1 | 2024 | 416 | 0.050 |
Why?
|
Logistic Models | 1 | 2017 | 13266 | 0.050 |
Why?
|
Liver | 1 | 2018 | 7562 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20124 | 0.050 |
Why?
|
Death Certificates | 1 | 2022 | 170 | 0.050 |
Why?
|
Cohort Effect | 1 | 2021 | 39 | 0.050 |
Why?
|
Chronic Disease | 1 | 2017 | 9347 | 0.050 |
Why?
|
Apolipoprotein C-II | 1 | 2021 | 14 | 0.050 |
Why?
|
Receptors, Lipoprotein | 1 | 2021 | 87 | 0.040 |
Why?
|
Lipoprotein Lipase | 1 | 2021 | 132 | 0.040 |
Why?
|
Time Factors | 2 | 2021 | 40065 | 0.040 |
Why?
|
gamma-Glutamyltransferase | 1 | 2019 | 140 | 0.040 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2022 | 669 | 0.040 |
Why?
|
Pericardium | 1 | 2022 | 679 | 0.030 |
Why?
|
Health Services | 1 | 2022 | 756 | 0.030 |
Why?
|
Cell Size | 1 | 2019 | 625 | 0.030 |
Why?
|
Postprandial Period | 1 | 2018 | 319 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2019 | 607 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2022 | 939 | 0.030 |
Why?
|
Lower Extremity | 1 | 2024 | 1226 | 0.030 |
Why?
|
Age Distribution | 1 | 2021 | 2858 | 0.030 |
Why?
|
Subcutaneous Fat | 1 | 2019 | 402 | 0.030 |
Why?
|
Health Facility Administration | 1 | 2015 | 29 | 0.030 |
Why?
|
Glucose Intolerance | 1 | 2019 | 580 | 0.030 |
Why?
|
HIV Infections | 1 | 2021 | 17533 | 0.030 |
Why?
|
Epigenomics | 1 | 2020 | 959 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1740 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2018 | 674 | 0.030 |
Why?
|
Quality Control | 1 | 2015 | 837 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2022 | 3222 | 0.020 |
Why?
|
Accreditation | 1 | 2015 | 477 | 0.020 |
Why?
|
Heterozygote | 1 | 2018 | 2794 | 0.020 |
Why?
|
Metabolome | 1 | 2018 | 1005 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2021 | 2643 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4335 | 0.020 |
Why?
|
Diabetes, Gestational | 1 | 2020 | 1263 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 16047 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2018 | 1892 | 0.020 |
Why?
|
Pregnancy | 2 | 2022 | 30260 | 0.020 |
Why?
|
Mental Health | 1 | 2023 | 3278 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2589 | 0.020 |
Why?
|
Infection Control | 1 | 2015 | 983 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2739 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7421 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12795 | 0.020 |
Why?
|
Program Evaluation | 1 | 2015 | 2499 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9591 | 0.020 |
Why?
|
Cross Infection | 1 | 2015 | 1427 | 0.020 |
Why?
|
Animals | 1 | 2018 | 168764 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 13024 | 0.010 |
Why?
|
Qualitative Research | 1 | 2015 | 3139 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2021 | 7851 | 0.010 |
Why?
|
Health Promotion | 1 | 2015 | 2208 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26346 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14071 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39193 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18071 | 0.010 |
Why?
|
Child | 1 | 2024 | 80564 | 0.010 |
Why?
|